In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million.
A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration
OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer Oxigene
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline In 2010, OXiGENE acquired VaxGen, Inc
Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503
On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). OXi4503 On June 20, 2016, OXiGENE officially became
Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.